Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE)‎ Study

Abstract EN

The aim of the study was to assess health-related quality of life (HRQoL) among metastatic soft tissue (mSTS) or bone sarcoma (mBS) patients who had attained a favourable response to chemotherapy.

We employed the EORTC QLQ-C30, the 3-item Cancer-Related Symptoms Questionnaire, and the EQ-5D instrument.

HRQoL was evaluated overall and by health state in 120 mSTS/mBS patients enrolled in the SABINE study across nine countries in Europe and North America.

Utility was estimated from responses to the EQ-5D instrument using UK population-based weights.

The mean EQ-5D utility score was 0.69 for the pooled patient sample with little variation across health states.

However, patients with progressive disease reported a clinically significant lower utility (0.56).

Among disease symptoms, pain and respiratory symptoms are common.

This study showed that mSTS/mBS is associated with reduced HRQoL and utility among patients with metastatic disease.